Showing results (521-530 of 658) with videos related to
Sort By:
Pageof 66
Cancer|August 10, 2005
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumorsJ Matthew McDonald, Siew Ju See, Ivo W Tremont, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2017
Novel Targeting of Transcription and Metabolism in GlioblastomaYu-Ting Su, Robert Chen, Herui Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II TrialShiao-Pei Weathers, Marta Penas-Prado, Be-Lian Pei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2018
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant GliomaFrederick F Lang, Charles Conrad, Candelaria Gomez-Manzano, et al.Journal of Proteome Research|November 5, 2014
Use of ENCODE resources to characterize novel proteoforms and missing proteins in the human proteomeCarol L Nilsson, Ekaterina Mostovenko, Cheryl F Lichti, et al.The Journal of Clinical Investigation|December 25, 2010
Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastomaFernanda I Staquicini, Michael G Ozawa, Catherine A Moya, et al.The Lancet. Oncology|July 9, 2017
Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trialAnita Mahajan, Salmaan Ahmed, Mary Frances McAleer, et al.International Journal of Radiation Oncology, Biology, Physics|August 31, 2010
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphomaNadia N Laack, Brian Patrick O'Neill, Karla V Ballman, et al.Neuro-Oncology|December 15, 2010
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaJohn H Sampson, Kenneth D Aldape, Gary E Archer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium studyJohn F de Groot, Kathleen R Lamborn, Susan M Chang, et al.Pageof 66